Although BRAF V600E mutation testing is widely used for thyroid nodules (5) —with its clinical relevance underscored by inclusion in authoritative guidelines, even for aggressive cancers, highlighting its central role (6)—the following critical evidence gaps persist in its application to Bethesda III nodules: (i) Subtype-dependent sensitivity disparities between classical PTC and follicular variants lack robust quantification (7);. This evidence concerns the gene BRAF and thyroid nodule.